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Background. CD56 expression was extensively investigated in cases of acute leukemia. Many studies
associated it with short overall survival, unfavorable outcome, lower rates or short complete remission, however
the results remain controversial.
Objectives. The aim of this study was to investigate the frequency and prognostic relevance of CD56
expression in patients with acute leukemia and to compare its value with other standard prognostic factors,
such as age, gender, leukocytosis, morphologic subtypes, extramedullary invasion, cytogenetic abnormalities
and performance status.
Methods. Forty cases of acute leukemia treated at Ain Shmas University hospitals were investigated. They
were classified by the French-American-British group (FAB) criteria, flow cytometry, and cytogenetics data.
They included twenty cases of acute myeloid leukemia (AML) and twenty cases of acute lymphoblastic leukemia
(ALL).
Results. CD56 positive expression was detected in nine cases of AML (45 %), and only in two patients with
ALL (10 %). The highest incidence of CD56 positivity was in FAB subtypes M1 (35 %) and M2 (35 %).Association
studies between CD56 expression and other prognostic factors in AML cases showed no significant association
with age, gender, clinical presentation, hematological data or cytogenetic risk groups. Incidence of relapse was
higher in AML patients expressing CD56 than those who did not (66.7 % vs 10 %, P=0.01). Higher death rates
were encountered in AML cases with CD56 expression than those without (55.6 % vs 10 %, P=0.032).
Conclusions. CD56 antigenic expression in AML cases represents an adverse prognostic factor. It should
be regularly investigated in cases of AML for better prognostic stratification and assessment.
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Introduction
Acute leukemia is a heterogeneous group of
disorders. They have various morphological, immu-
nophenotypic and cytogenetic patterns. Identifying
these characteristics is useful for prediction of the-
rapy responses and prognosis of the disease [1].
Several phenotypic markers demonstrated to have
clinical significance including detection of minimal
residual disease [2, 3] rate and duration of complete
remission (CR), disease-free survival, and overall
survival (OS) [3].
CD56, a neural cell adhesion molecule (NCAM),
is an early described natural killer cell-associated
antigen. It mediates cell-to-cell interaction and is
possibly involved in cell-mediated cytotoxicity. This
antigen is also found in a subset of CD3+ cytotoxic
T-cells and a small population of CD4+ T-cells and
monocytes [4]. It is expressed in various hemato-
poietic neoplasms, including acute myeloid leuke-
mia(AML) [5], acute lymphoblastic leukemia (ALL)
[6], lymphoma [7], and myeloma cells [8]. Being a
cell adhesion molecule, CD56 expression on tumor
cells is believed to play a role in their localization
with involvement of extramedullary metastasis [9].
The prognostic value of CD56 expression in
cases of acute leukemia has been extensively
investigated but with few consistent results [3]. Some
investigators associated CD56 expression with short
OS [5, 10–12], and lower CR rates [10] in AML
patient. Although Ferrara et al.[12] reported short OS
in AML cases expressing CD56; they could not detect
association of this marker with the rate of CR in M3
AML cases. Moreover, Chang et al. studied 379
cases of AML including all subtypes except M3 and
reported that the CR rate was not associated with
CD56 expression, but with CD34 and HLA-DR
expression [13].
The aim of this study is to evaluate the prognostic
role of CD56 expression in newly diagnosed acute
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leukemia including AML and ALL cases and correlate
the results with other prognostic factors.
Methods
Patients
This study was carried out on 40 newly diagno-
sed cases of acute leukemia. It included 20 AML
and 20 ALL patients presented at the Hematology/
Oncology Clinics in the Internal Medicine and Pe-
diatric Hospitals, Ain Shams University, Cairo, Egypt.
Diagnosis and classification of acute leukemia
was based on WHO (2008) [14] and FAB [15] criteria.
Bone marrow and peripheral blood samples obtained
at presentation were examined for morphology,
immunophenotyping and complementary cytoge-
netics. Another bone marrow samples were taken
on the 28th day to evaluate response to induction
therapy. Response to treatment was considered
ineffective if more than 5 % blasts were detected in
BM on the 28th day.
Immunophenotyping
Flow-cytometric analyses were performed as
previously described [16]. The reactivity for the
following markers was analyzed: a panel of
fluorescein isothiocyanate (FITC)/phycoerythrin (PE)
conjugated monoclonal antibodies to B-lineage
markers (CD19, CD10, CD20, CD79a), T-lineage
markers (CD2, CD3, CD5, CD7, cytCD3), myeloid
markers (CD13, CD33, CD15, MPO, CD61,
glycophorin, CD117), monocytic markers (CD14),
and common progenitors markers (CD34, HLA-DR),
supplied by Beckman Coulter, France. In addition,
MoAb NCAM-PE (clone NCAM) (MiltenyiBiotec,
Germany) for detection of CD56 was used. Cells
were considered positive for a certain marker when
20 % of blasts expressed it, except for CD56, CD34
and intracellular MPO, where expression of 10 %
of blasts was reported as positive.
Cytogenetic analysis
Leukemic cells were cultured, and the chro-
mosomes were banded. Cytogenetic abnormalities
were determined according to the International
System for Human Cytogenetic Nomenclature [17].
Cytogenetic results were categorized into favorable,
intermediate and unfavorable risk group.
Statistical analysis
Statistical analysis of the data was performed
by using SPSS 15 software package and Windows
7® operating system. Categorical data parameters
were presented in terms of frequency and percent
age. Comparisons and associations that involve
categorical variables were done by chi square test
or Fisher exact test depending on the nature of the
data. Continuous data parameters were described
as middle, standard deviation (SD), median and
interquartile range (IQR).
Results
Forty acute leukemia patients (20 AML and 20
ALL) were enrolled in this study. Table 1 summarizes
age, gender, and clinical findings in the studied AML
and ALL cases.
According to FAB criteria, AML patients were
classified into: 7 (35 %) M1, 7 (35 %) M2, 4 (20 %)
M3, one (5 %) M4 and one (5 %) M5 case. ALL
were classified into 17 (85 %) B-ALL and 3 (15 %)
T-ALL cases.
Successful mitosis was encountered in 18/20
(90 %) AML cases. Ten of these cases (55 %) were
categorized as favorable [t(8:21), inv(16),t(15:17)],
6 (33.3 %) were intermediate (+8, normal) and 2
(11 %) cases were poor risk group [t(9:22), 11q23].
Successful mitosis was obtained in 12(60 %) of ALL
cases. Three ALL cases (25 %) were classified as
favorable risk (del 6q, hyperdiploidy>50), 5(41 %)
were intermediate risk (normal), and 4(33 %) were
poor risk group ( t(9:22), hypodyploidy<45).
Our follow up of AML cases during induction
period showed that 12 (63.2 %) AML cases showed
good response to chemotherapy and achieved
complete remission, while 7 patients (36.8 %) relap-
sed, and one case was missed. Six of the relapsed
patients died. Meanwhile, 14 (70 %) ALL patients
showed good response to chemotherapy and
achieved complete remission, while five cases
(25 %) relapsed, 3 of them died.
CD56 expression and association studies:
Nine AML cases (45 %) were positive for CD56,
while 11 (55 %) were negative. CD56 and CD34
coexpression was found in 2 cases (10 %). None of
our AML cases co-expressed CD56 and CD7.Only
2 ALL cases (10 %) expressed CD56. One ALL case
co-expressed CD56 and CD34.There was a
statistically significant positive association between
CD56 positive expression and CD117 in AML
(p<0.05). No significant association was found
between CD56 positive expression and immuno-
Table 1. Demographic and clinical findings in AML
and ALL cases
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phenotype profile of ALL (P>0.05). Because of the
small ALL sample, expressing CD56, the analysis
of results of these cases questions its statistical
reliability.
No significant association was detected between
CD56 positive expression and age (P=0.806)
(Table 2), gender, clinical or hematological data in
AML patients (Table 3). Similarly, we could not
associate this marker expression with cytogenetics
risk groups (P=0.118) (Table 4).
AML cases showed a statistically significant
association between CD56 positivity and poor
outcome. We missed one case and only 19 patients
were evaluated including nine CD56 positive and
Table 2. Association studies between CD56 and age in AML patients
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Table 3. Association studies between CD56 expression and gender, clinical and hematological
data in AML patients
n: number of cases, Hb: hemoglobin, WBC: white blood counts, PLT: platelets count, PB: peripheral blood, BM: bone
marrow
Sig: significant, NS: non-significant.
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Table 4.Association between cytogenetics risk groups and CD56 expression in AML patients
*2 cultures failed, n: number, Sig: significant, NS: non-significant
n = number of cases, NS: non-significant.
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10 negative cases. Six patients out of the 9 positive
CD56 cases (66.7 %) relapsed and only 3 (33.7 %)
developed remission. Five (55.6%) of the CD56
expressing patients died. On the other hand, the
CD56 negative patients group showed one (10 %)
case relapse and death, while nine (90 %) patients
developed remission.
Statistical comparison between those patient
with CD56 expression and those without showed
significant increased incidence of relapse (P=0.01)
(Table 5, Figure 1) and deaths (P=0.032) among
patients expressing CD56 (Table 5, Figure 2).
Discussion
Acute leukemia comprises a heterogeneous
group of diseases that differ in their etiology,
pathogenesis, and prognosis. Our study investigated
the prognostic significance of CD56 expression in
these cases to evaluate its association with other
prognostic factors, and its influence on the outcome
during induction therapy.
CD56 positivity was observed in 45 % of AML
cases, and 10 % ALL cases. These results are in
concordance with Fischer et al. [18] who reported
that CD56 expression was not restricted to AML
samples and could be detected in both B-cell and
T-cell ALLs (14 %) as well. They concluded that it is
not reliable for lineage distinction between AML and
ALL. However, Montero et al. [19] reported exp-
ression of this marker in only 4 patients (2 %) out of
200 ALL cases. These differences could be explained
by lower number of cases in our study as compared
to 200 cases studies, or due to methodology
variation. The study of Fischer et al. [18] investigated
CD56 in 452 newly diagnosed T-ALL patients
included in the GMALL trial. The marker was
expressed in 13.9 % of patients, predominating in
the non-thymic subtypes, whereas thymic T-ALL was
most common in the CD56 negative group. In addi-
tion, the authors reported that CD56 expression was
associated with higher resistance to therapy.
Our statistical analysis showed that CD56
expression in AML cases was not associated with
age (Table 2), sex, or any laboratory variables in-
cluding blasts counts, WBC, hemoglobin concen-
tration or platelets counts (Table 3). Similarly Yang
et al. [20] could not associate CD56 expression with
any laboratory variables in AML cases. However,
other investigators [1] reported a higher proportion
of CD56 expression in men.
The presence of lymphadenopathy, hepato-
megaly, and splenomegaly provide an indirect
measurement of leukemic cell burden. We could
not detect significant association of positive CD56
and presence of any of these clinical conditions in
AML cases. Also, no significant association was
found with other clinical features as presence of
fever, pallor or bleeding tendency (Table 3). These
findings are compatible with other published data
(Table 18, 21).
Our work detected only two cases of ALL
expressing CD56, these were of B-ALL subtype and
were not characterised by hepatomegaly or spleno-
megaly. Although Ravandiet al. [6] considered that
Table 5. Association between treatment outcome, fate and CD56 expression in AML patients
n = number of cases, *= one case was missed.
Fig. 1: Association between CD56 expression and treatment
outcome in AML patients.
Fig. 2. Association between CD56 expression and mortalityin
AML patients
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CD56 expression predicts occurrence of CNS dise-
ase in ALL, none of our positive CD56 ALL cases
had CNS involvement. In addition, no association
was found between CD56 expression and demo-
graphic, clinical presentation or laboratory tests
(P>0.05). However, the low number of ALL cases
expressing CD56 incapacitated our statistical and
association analysis and doubts these results.
CD56 expression was heterogeneous in different
FAB subtypes. The more frequent CD56 expression
was observed in M1 (35 %) and M2 (35 %).
Allegrettiet al. [1] detected highest incidence of CD56
positivity among FAB subtypes M4 and M5, while
Di Bona et al. [22] found more CD56 expression in
M5 patients. These differences could be attributed
to different number of patients in sample.
To elucidate the prognostic value of CD56, its
expression was studied in relation to treatment
response in our AML patients. CD56 expression was
shown to be significantly related to response to
chemotherapy with higher relapse (66.6 % vs 10 %,
P=0.010) and death rate (55.5 % vs 10 %, P=0.32)
among patients with positive CD56 expression as
compared to patients without it. The investigation
[1] in a single center in Brazil that investigated cohort
of 48 AML patients supported our results and
documented the association of CD56 expression with
worse prognosis. The authors observed higher death
rate during induction in the CD56 positive cases.
Their study detected short OS among cases with
positive CD56 expression compared to CD56
negative patients. Similarly, Baer et al. stated that
CD56 expression was significantly correlated with a
short complete remission (CR) period and low OS
[21].On the contrary, Ferrara et al. reported that there
was no association between CD56 expression and
the rate of CR in patients with AML [12]. Moreover,
Di Bona et al. failed to demonstrate the influence of
CD56 positivity on CR duration or OS in 171 studied
cases of AML [22].
AML with t(8;21) is considered a group with
favorable outcome, usually marked by high CR rate
and prolonged disease-free survival. We encoun-
tered five cases with this subtype (25 %), three of
these patients (60 %) expressed CD56 and they
relapsed and died. Although the small number of
our cases (n=5) questions the significance of these
results, the fatal outcome is too striking to be ignored.
A previous large-scale studies investigated 144 AML
patients with t(8;21) in the JALSGAML97 study.
Univariate analysis showed that increased white
blood cell counts (WBC20109/L),CD19 negativity,
and CD56 positivity were critical adverse factors for
relapse after CR. Multivariate analysis showed that
WBC count and CD56 expression were independent
adverse risk factors. The authors concluded that
CD56 expression has a possible role in risks tratifi-
cation for patients with AML with t(8;21) [23].
Our study included only four cases of promyelo-
cytic leukemia (APL), three of these patients ex-
pressed CD56 (75%). Relapses were evident in two
(50%) of those cases expressing this marker. The
clinical significance of CD56 expression was studied
in a large series of patients with APL, treated with
all-trans retinoic acid and anthracycline-based
protocols. The authors documented that expression
of CD56 is an independent adverse prognostic factor
for relapse in these patients and suggested imple-
menting this marker as a risk-adapted therapeutic
strategies in APL [24].
Conclusions
The association between CD56 expression and
the poor response of AML to current treatments is
not fully understood. Raspadori et al. [25] hypo-
thesized that CD56+ AML blasts might overexpress
p-glycoprotein (PGP), a multidrug-resistance (MDR)
related protein, and reduce responsiveness to
chemotherapy. Their data underlined the indepen-
dent negative prognostic role of CD56 and PGP
expression in cases of acute myeloid leukemia. In
contrast, other investigators [26] showed that CD56
expression did not correlate with PGP expression,
function, or with expression of the other MDR pro-
teins. Other authors [27] have shown that CD56
expression by AML cells is positively regulated by
RUNX1 p48 and is negatively regulated by other
splice variants. Their findings suggest that p48 and
RUNX1-driven NF-B and bcl2 pathways are new
elements for targeted treatments in high-risk
CD56AMLs.
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